Skip to content
Trial Eligibility
Menu

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

NCT00867269

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Background: Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and diseases. Objectives: To characterize the natural history with regard to CD4+ T cell count and onset of infection, malignancy, and autoimmunity. To describe the immunological status of patients affected by ICL while providing the best possible standard therapy to eradicate opportunistic infections.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Idiopathic CD4+ Lymphocytopenia
  • Cryptococcal Meningitis
  • Warts

Eligibility basics and study details

Study type
Observational
Phase
Not applicable
Ages
18 years and older
Sex
All
Healthy volunteers
Accepted
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Last updated on ClinicalTrials.gov
October 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Maryland · 1

  • National Institutes of Health Clinical Center · Bethesda, MD

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.